2 weeks Ago By Defense World Staff
Century Therapeutics, Inc. ( NASDAQ:IPSC – Get Free Report ) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 3,280,000 shares, an increase of 15.
9% from the August 31st total of 2,830,000 shares. Based on an average trading volume of 338,700 shares, the short-interest ratio is currently 9.7 days.
Currently, 10.1% of the shares of the stock are sold short. Century Therapeutics Price Performance Shares of IPSC stock traded up $0.
10 during trading on Monday, hitting $1.71. 535,563 shares of the stock traded hands, compared to its average volume of 244,853.
Century Therapeutics has a 52-week low of $1.28 and a 52-week high of $5.51.
The firm has a market capitalization of $144.50 million, a P/E ratio of -0.77 and a beta of 1.
36. The firm’s fifty day moving average price is $1.78 and its 200-day moving average price is $2.
70. Century Therapeutics ( NASDAQ:IPSC – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.
38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12.
The business had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.55 million.
Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%.
As a group, equities research analysts expect that Century Therapeutics will post -1.8 earnings per share for the current year. Institutional Investors Weigh In On Century Therapeutics Analysts Set New Price Targets IPSC has been the topic of several recent research reports.
HC Wainwright lowered their target price on Century Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, August 15th.
Piper Sandler upped their target price on Century Therapeutics from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Monday, June 17th.
Finally, Rodman & Renshaw assumed coverage on Century Therapeutics in a report on Thursday, August 8th. They set a “buy” rating and a $6.00 price target on the stock.
Read Our Latest Stock Report on IPSC About Century Therapeutics ( Get Free Report ) Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. Read More Five stocks we like better than Century Therapeutics Biggest Stock Losers – Today’s Biggest Percentage Decliners TJX Stock: A Buying Opportunity Before the Holiday Rush Trading Stocks: RSI and Why it’s Useful Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge Health Care Stocks Explained: Why You Might Want to Invest Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
